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INTRODUCTION
Hyperlipidemia  is  commonly  found  in  normal  population  associated 
with pathologies such as hypertension and atherosclerosis. In pregnant women 
however,  hyperlipidemia  has  serious  implications.  The  increased  nutritional 
requirement  of  the  fetoplacental  unit  and  the  endocrine  profile  during 
pregnancy  could  explain  the  biochemical  changes  in  lipid  metabolism  of 
pregnancy.
The  major  lipids  of  human  body  are  phospholipids,  cholesterol, 
triglycerides  and  cholesteryl  esters.  These  insoluble  lipids  are  transported 
through blood as  lipoproteins  consisting of  lipids  and one or  more  specific 
proteins called apolipoproteins. In pregnancy, increase in female sex hormones, 
and lipolysis due to placental lactogen, cause an increase in lipid synthesis and 
metabolism resulting in increased cholesterol,  triglycerides and phospholipid 
concentrations.
Ideally,  sufficient  maternal  nutrients  provided  across  uteroplacental 
circulation function efficiently to meet the demands of the growing fetus. If 
balanced  interaction  between  mother  and  fetus  is  disturbed  it  leads  to 
Intrauterine  Growth  Restriction  (IUGR)  which  is  associated  with  higher 
perinatal mortality and morbidity. Growth restricted fetuses are those born with 
birth weight 2500g or less.
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More  studies  on  biochemical  changes  in  pregnancy  are  necessary  to 
characterise the excessive gestational lipolytic responses. This would enable us 
to determine if  the changes in lipoprotein profile  during pregnancy imply a 
greater  atherogenic  risk  with  possible  repercussions  on  fetal  growth  and 
development.  Haemorrheological  modifications  in  growth  restricted 
pregnancies  are  partly  secondary  to  changes  in  high  density  lipoprotein 
metabolism. Changes in apolipoprotein A-1 could be a good marker for the 
early detection of intrauterine growth restricted pregnancies.
In  this  study,  the  lipid  fractions  and  apolipoprotein  A-1  in  normal 
pregnancies  and  pregnancies  with  intrauterine  growth  restriction  were 
determined and compared.
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REVIEW OF LITERATURE
Apolipoproteins  are  proteins  found  on  the  surface  of  the  lipoprotein 
complex. Apolipoproteins bind to specific enzymes or transport proteins on the 
cell membranes and direct the lipoproteins to the proper site of metabolism.
LIPOPROTEINS    
Lipoproteins  are  large  molecules  that  transport  lipids,  primarily 
triglycerides and cholesterol through the blood. A typical lipoprotein consists 
of  a  lipid  core  of  mainly  non  polar  triacylglycerol  and  cholesteryl  ester 
surrounded  by  a  single  surface  layer  of  amphipathic  phospholipids  and 
cholesterol  molecules.  These  are  oriented  such  that  the  polar  groups  face 
outward to the aqueous medium1. Lipoprotein molecules differ in their relative 
lipid and apolipoprotein composition, size, density and function. Lipoproteins 
can be  separated depending on their  density  using ultracentrifugation  or  on 
their electrophoretic mobility2. The five major groups of lipoproteins and their 
functions are given below
1) Chylomicrons (CM) –Transport of exogenous triglycerides.
2) Very  low  density  lipoproteins  (VLDL  or  pre  beta  lipoproteins) 
Transport of endogenous triglycerides. 
3) Intermediate  density  lipoproteins  (IDLor  broad  beta  lipoproteins) 
Precursor of Low density Lipoproteins
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     4) Low density lipoproteins (LDL or beta lipoproteins) Cholesterol transport
5) High  density  lipoproteins  (HDL  or  alpha  lipoproteins)  Reverse 
cholesterol transport.3
The source, size and composition of the various lipoproteins are given in 
chart 1  
CHART 1
Composition of the Lipoproteins in plasma of humans 
Lipo
proteins Source
Diam
eter
(nm)
Density
(g/ml)
Composition
% 
Protein
% 
Lipid
Main
Lipid
Apolipo
proteins %
CM Intestine 90-10
00
< 0.95 1-2 98-99 TGL A-1 : 7.4
A-11 : 4.2
A-IV, B48:22.5
CI, CII, CIII : 66
CM  
remnants 
CM 45-15
0
< 1.006 6-8 92-94 TGL
PL
C
B48, E
VLDL Liver
(intestine)
30-90 0.95-1.0
06
7-10 90-93 TGL B 100 : 36.9,
CI,CII,CIII :49.9
IDL VLDL 25-35 1.006-1.
019
11 89 TGL
CE
B100 : 50-70, E
CI,CII,CIII : 5- 10
LDL VLDL 20-25 1.019-1.
063
21 79 CE B100 : 98
HDL,
HDL1
HDL 2
HDL3
Pre 
βHDL
Liver, 
intestine, 
VLDL, CM
20-25 1.019-1.
063
32 68
10-20 1.063-1.
125
33 67
5-10 1.125-1.
210
57 43
< 5 >1.210
PL
CE
A I :  67 ,A II :  22,
A IV, B100 - Trace; 
C-I,C-II, C-III : 5 - 11
 D, E; 
A-1
Courtesy : Harper 26th Edition
Tietz - 3rd edition
The  physiological  functions  of  the  lipoproteins  involve  a  series  of 
complex  metabolic  processes  in  which  changes  and  exchanges  occur 
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continuously  between  the  various  lipoproteins.  This  is  referred  to  as  the 
lipoprotein cascade.4 As the percentage of apolipoprotein A-1 is found to be 
highest in High density lipoprotein, a detailed description of the lipoprotein and 
its metabolism, in relation to its function has been discussed below.
High density Lipoproteins
High density lipoproteins are secreted from both the liver and intestine. 
About 50% of high density lipoprotein mass is protein, 30% is phospholipid 
and  20%  cholesterol7.  The  high  density  lipoprotein  fraction  comprises  of 
several  distinct  subclasses,  differing  in  their  density  particle  size,  or 
apolipoprotein composition. At least three well defined high density lipoprotein 
subgroups have been studied. These include high density lipoprotein1 (HDL1) 
high density lipoprotein2 (HDL2) and high density lipoprotein3 (HDL3) 4. 
High density lipoprotein1 (HDL1) 
High density lipoprotein1 (HDL1) is found in the blood of diet induced 
hypercholesterolemic  animals.  It  is  rich  in  cholesterol  and  contains  only 
apolipoprotein  E.  It  is  taken  up  by  the  liver  via  apolipoprotein  E  remnant 
receptor and also by low density lipoprotein receptor. It is for this reason that 
the latter are also called B100 E receptors. 5
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High density lipoprotein2 (HDL2). 
It  is  rich  in  cholesterol  ester.  It  is  involved  in  reverse  cholesterol 
transport.  Its  concentration  in  the  blood  is  inversely  proportional  to 
atherosclerosis.  High  density  lipoprotein2 (HDL2)  contains  more  lipid  and 
apolipoprotein A-1 levels than high density lipoprotein3 (HDL3) 4 
High density lipoprotein3 (HDL3)
It is considered to be the smaller and denser precursor of high density 
lipoprotein2 (HDL2).
Reverse Cholesterol Transport
High  density  lipoproteins  are  the  main  mediators  of  the  reverse 
cholesterol  transport,  whereby  cholesterol  synthesized  or  deposited  in 
peripheral cells is returned to the liver.
The process begins with the removal of free cholesterol from the cell 
membranes  to  nascent  high  density  lipoproteins  secreted  by  the  liver  and 
intestine. The nascent high density lipoproteins consist of discoid phospholipid 
bilayers  containing  apolipoprotein  A-1  and  free  cholesterol.  Lecithin 
cholesterol  acyl  transferase  (LCAT)  binds  to  the  disk  and  is  activated  by 
apolipoprotein A-1. Surface phospholipid is hydrolysed by LCAT converting 
phospholipid into lysolecithin and free cholesterol into ester cholesterol. The 
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non polar cholesteryl esters move into the hydrophobic interior of the bilayer 
whereas  lysolecithin  is  transferred  to  plasma  albumin.  In  this  process,  the 
nascent high density lipoprotein is converted to the spherical lipid rich high 
density lipoprotein3 (HDL3) 1,5. 
The smaller high density lipoprotein3 (HDL3) accepts cholesterol from 
the tissues via the ATP binding cassette transporter – 1 (ABC - 1). ABC – 1 is a 
member of a family of transporter proteins that couple the hydrolysis of ATP to 
the binding of the substrate cholesterol enabling it to be transported across the 
membrane to be taken up by the high density lipoprotein. As more and more 
cholesterol  is  accepted  by  high  density  lipoprotein3 (HDL3)  the  lipoprotein 
particle  increases  in  size  to  form  the  less  dense  high  density  lipoprotein2 
(HDL2). Mature high density lipoprotein2 (HDL2) are taken up by the liver and 
steroidogenic tissues where the receptor for high density lipoprotein namely 
class B scavenger receptor B1 (SR – B1) are found. High density lipoprotein2 
(HDL2) binds to the receptor via apolipoprotein A-1 and cholesteryl ester is 
selectively delivered to the cells, but the particle itself including apolipoprotein 
A-1 is not taken up.1   
The cycle is completed by the reformation of high density lipoprotein3 
(HDL3) either after selective delivery of cholesteryl ester to the liver via the 
scavenger receptor B1 or by hydrolysis of high density lipoproteins2 (HDL2) 
phospholipid  and  triacylglycerol  by  hepatic  lipase.  In  addition,  free 
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apolipoprotein  A-1  released  by  this  process,  forms  pre  Beta  high  density 
lipoprotein  after  associating  with  a  minimum  amount  of  phospholipid  and 
cholesterol. Pre Beta high density lipoprotein is the most potent form of high 
density  lipoproteins  in  inducing  cholesterol  efflux  from the  tissues  to  form 
discoidal high density lipoprotein. Surplus apolipoproteins A-1 is destroyed in 
the kidney.1,5 
An alternate pathway is present which transfers the cholesteryl esters 
formed in High density Lipoprotein to Very Low Density Lipoproteins and its 
remnants.  Cholesterol ester transfer protein is a protein found in association 
with High density lipoprotein that facilitates the transfer of cholesteryl ester 
from high  density  lipoprotein  to  very  low density  lipoprotein,  intermediate 
density lipoprotein and low density lipoprotein in exchange for triacylglycerol. 
This, thus prevents the product cholesteryl ester inhibiting the LCAT activity in 
high density lipoprotein.4 By this alternate pathway also, the cholesteryl ester 
formed by LCAT finds its way to the liver via the VLDL remnants namely IDL 
and LDL.
The  above  said  metabolism  of  HDL  involving  reverse  cholesterol 
transport is clearly depicted in Fig.1.
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APOLIPOPROTEINS
Apolipoprotein  is  the  protein  part  of  the  lipoprotein  molecule. 
Apolipoproteins  have  several  roles  and  their  distribution  characterizes  the 
lipoprotein. Apolipoproteins have three general functions.
1) They provide the structural element to the lipoprotein particles and thus 
are important in maintaining stability
2) They act as ligands for specific receptors
3) They  act  as  activators  or  inhibitors  of  specific  enzymes  involved  in 
lipoprotein metabolism1
Apolipoprotein A-1
Apolipoprotein  A-1  is  the  major  protein  component  of  high  density 
lipoprotein and comprises approximately 70% of the total protein mass ranging 
from  32%  to  57%  of  the  high  density  lipoprotein  particle.  The  molecular 
weight of Apolipoproteins A-1 is reported to be 28.3KDa6.
In  humans  Apolipoprotein  A-1  is  synthesized  both  in  the  liver  and 
intestine.  Civeria F, has stated that Apolipoprotein A-1 levels in plasma are 
related to hepatic Apolipoprotein A-1 mRNA levels, and that transcription of 
apolipoprotein A-1 mRNA from the apolipoprotien A – 1 gene seems to be an 
important factor in the control of apolipoprotein A-1 production7.
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The  gene  encoding  apolipoprotein  A-1  is  a  member  of  the 
apolipoprotein  multigene  super  family  which  includes  genes  encoding 
exchangeable  apolipoproteins  (apolipoproteins  A-1,  A-11,  C’s  and  E).  The 
gene for apolipoprotein A-1 has been mapped on chromosome 11q 23 8.
Structure of Apolipoprotein A-1
Apolipoprotein A-1 was one of the first apolipoproteins to be identified 
and characterized.  It  is  a  single  polypeptide  chain consisting  of  245 amino 
acids with glutamic acid as the C terminal residue and aspartic acid as the N 
terminal residue. The N terminal domain (1 - 99) residues is highly conserved 
while the central (100 - 186) and C terminal domain (187 - 245) residues shows 
conservative substitutions between species.8  
Apolipoprotein A-1 shown in Fig.2 has a high content of alpha helix 
structure.  It  consists  largely  of  six  tandem  22-residue  segments  of  similar 
sequence that each has a high propensity for forming an alpha helix followed 
by  a  beta  turn.  These  putative  alpha  helices  have  their  hydrophobic  and 
hydrophilic residues on opposite sides of the helical cylinder. The polar helix 
face has a dipolar character,  because its  negatively charged residues project 
from the centre of the face, whereas its positively charged residues are located 
at its edges. The phospholipids are arranged with their charged groups bound to 
oppositely charged residues on the polar face of the helix and with the first few 
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methylene groups of their fatty acid residues in hydrophobic association with 
the non polar face of the helix.12
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Proline  present  at  the  first  position  of  almost  every  22  amino  acid 
residues  often  form  beta  turns  or  kinks  between  helices  and  are  therefore 
essential  for  the  secondary  structure  of  apolipoproteins.  The  presence  of  a 
proline  residue  appears  necessary  in  defining  the  structural  and  functional 
properties  of  apolipoprotein  A-1,  which  associates  mostly  with  small 
lipoproteins (high density lipoprotein)8.        
Functions of individual domains
1) The N terminal domain (residues 1-43) may be important for the stability 
of the protein in the lipid free state and indirectly modulate its interaction 
with lecithin cholesterol acyl transferase.
2) The central domain has a function in the regulation of the interaction with 
phospholipid  and  is  responsible  for  the  plasticity  of  the  molecule  by 
allowing its association with varying amounts of phospholipid. The domain 
formed by residues 100 – 143 and within it by the helix containing residues 
100 – 121 has a very significant role in the binding of phospholipids both 
in vitro and vivo. A part of central domain formed by residues 144 – 186 
forms the site involved in lecithin cholesterol acyl transferase activation.
3) The C terminal domain appears crucial for the ability of apolipoprotein A-1 
to promote cholesterol efflux from cholesterol loaded macrophages by the 
efficient binding of C terminal domain to the cell. Lecithin cholesterol acyl 
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transferase  activation  requires  a  certain  affinity  for  phospholipids 
contributed by the C terminal domain (187 – 243) and within it probably 
the last helix (220 – 241)8.
Lipid free form of Apolipoprotein A-1.
Lipid free form of apolipoprotein A-1 is a loosely folded and relatively 
flexible  structure  which  may  allow  rapid  lipid  interaction  of  exposed 
hydrophobic portions of the protein. The N terminal sequence residues 1 – 43 
of  apolipoprotein  A-1,  apparently  not  required  for  lipid  binding  may  be 
important  for  the  stabilization  of  lipid  free  form  of  apolipoprotein  A-1  in 
solution. Lipid free apolipoprotein A-1 typically exhibits an alpha helix content 
of 40 – 50%, while in association with phospholipid the alpha helix structure 
increases approximately 75%  depending on the type of lipids and complexes 
formed8.  
Interaction of Apolipoprotein A-1 with Lipids- Role of amphipathic helices
The  properties  of  synthetic  peptides  that  correspond  to  each  of  the 
predicted  apolipoprotein  A-1  helical  segments  shows  that  peptides 
corresponding to  helices  44;-65 and 220;-241 have been found to  associate 
with lipids with a significant affinity. This result has been attributed to a deeper 
penetration of these two helices into the lipid interface, as compared to other 
helices. The two extreme helices of apolipoprotein A-1 may initiate the binding 
14
to  phospholipid,  followed  by  a  cooperative  binding  of  the  other  helices. 
However,  recent  in  vitro  studies  showed  that  the  central  domain  of 
apolipoprotein A-1, the helix formed by residues 100;-121 is very important for 
the stabilization of the lipid apolipoprotein complex, while helices spanning 
residues  122;-186  contribute  to  the  initial  rates  of   lipid  apolipoprotein 
association.
Lp A-1 complexes (Apolipoprotein A-1 containing lipoprotein complexes)
Apolipoprotein A-1 can form discoidal as well as spherical complexes. 
Discoidal  complexes  could  contain  two,  three  or  more  molecules  of 
apolipoprotein A-1 per particle. The disc formed by a phospholipid bilayer can 
accommodate  apolipoprotein  A-1  amphipathic  alpha  helices,  parallel  to  the 
phospholipid  acyl  chains.  In  small  discoidal  apolipoprotein  A-1  containing 
lipoproteins,  two  helices  do  not  interact  with  the  lipid  interface  possibly 
because of a reduced affinity for lipids. However in large discoidal complexes, 
these helices which have been termed as hinge domain, interact with lipids and 
can  therefore  allow  one  molecule  of  apolipoprotein  A-1  to  associate  with 
varying amount of lipid8 as shown in Fig.3.
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Functions of Apolipoprotein A-1
1) Lecithin Cholesterol Acyl Transferase activation 
The lecithin cholesterol acyl transferase glycoprotein consisting of 416 
amino acids displays two actitivties, a phospholipase A2 activity since it can 
hydrolyse the sn2 fatty acid from phosphatidyl choline and an acyl transferase 
activity. 
Apolipoprotein  A-1  was  the  first  described  activator  of  lecithin 
cholesterol  acyl  transferase  and  is  its  most  potent  in  vivo  activator.  This 
reaction requires three steps. First lecithin cholesterol acyl transferase binds to 
the substrate (high density lipoprotein) and / or the activator, and in a second 
step lecithin cholesterol acyl transferase hydrolyses the fatty acid at the sn2 
position of the phospholipid. The third and final step is the transesterification 
of cholesterol and concomitant release of cholesteryl ester.
Other apolipoproteins also activate lecithin cholesterol acyl transferase 
but below 20% of that observed for apolipoprotein A-1. The mechanism by 
which apolipoprotein A-1 activates lecithin cholesterol acyl transferase is still 
unknown,  but  may  involve  a  direct  interaction  between  2  helices  of 
apolipoprotein  A-1  and  residues  152  -169  of  lecithin  cholesterol  acyl 
transferase. Positively charged residues present in both the helices 144 – 165 
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and 166 – 186 of apolipoprotein may interact with negatively charged residues 
found on the lecithin cholesterol acyl transferase helix8.       
2. Cholesterol efflux from cells
Apolipoprotein A-1 bound to high density lipoprotein is important  in 
cholesterol efflux from cells via reverse cholesterol transport. The phospholipid 
content of high density lipoprotein could affect cholesterol efflux between cells 
and  lipoproteins.  The  ability  of  apolipoprotein  A-1  to  interact  with  lipid 
surfaces suggests a possible role for its amphipathic alpha helices to promote 
cellular cholesterol efflux from the plasma membrane. The central domain of 
apolipoprotein  A-1  is  more  labile  and  could  interact  more  easily  with  the 
plasma membrane to promote cellular cholesterol efflux.
A  second  mechanism  which  involves  the  direct  binding  of 
apolipoprotein A-1 to the cell membrane and causes the transfer of intracellular 
cholesterol  to  the  plasma  membrane  is  called  binding  and  translocation 
dependant cholesterol efflux. 
3) Solubility of lipoproteins: 
The apolipoprotein imparts water solubility to the hydrophobic central 
core of the cholesteryl esters and triglycerides in the high density lipoprotein 
particle.
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Serum levels of Apolipoprotein A-1 range from 120 to 150 mg/dl in 
males and 130 to 160 mg/dl in females.
Mutations of Apolipoprotein A-1 
Naturally occurring Apolipoprotein A-1 mutations 
a. Mutations  of  the  N-terminal  domain  –  several  naturally  occurring 
mutations  in  the  N-terminal  domain  have  been  identified  and  these 
mutations  are  often  associated  with  amyloidosis.  This  disease  is  a 
disorder  of  protein metabolism in which autologous proteins  or  their 
fragments associate with amyloid precursor proteins and are deposited 
as fibers in the tissues. Small N-terminal fragments of Apolipoprotein 
A-1 variants have been found in some individuals with amyloidosis. The 
presence of an extra positive charge in the N-terminal domain may be 
responsible for the formation of amyloid deposits. 
b. Mutations of the central domain. Several naturally occurring mutations 
in  the  central  domain  of  Apolipoprotein  A-1  have  been  described. 
However. few of them have been associated with clear defects in lipid 
binding properties.  Only  when the  secondary structure  of  the  protein 
was clearly modified, were impaired lipid binding properties observed.
c. Mutations of the C-terminal domain – very few natural mutations have 
been observed in the C-terminal domain of Apolipoprotein A-1. Funke 
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et al has described a mutant in which a frame shift mutation leads to a 
modification  of  residues  203-229  and  a  smaller  mature  protein  (229 
residues) was formed. This patient revealed corneal opacity and reduced 
plasma lecithin cholesterol acyl transferase activity.8
Apolipoprotein A-1 Deficiency 
Familial  apolipoprotein  A-1  defects  may  be  caused  by  complete 
deficiency  of  the  apolipoprotein  A-1  gene,  or  by  mutations  in  the 
apolipoprotein A-1 gene. Genetic deficiency of apolipoprotein A-1 may be due 
to the deletion of the gene or to nonsense mutations that prevent the synthesis 
of apolipoprotein A-1. Patients with this disorder sometimes display cutaneous 
xanthomas.  The  risk  of  premature  cardiovascular  disease  in  patients  with 
apolipoprotein A-1 deficiency may be increased but the onset  of symptoms 
varies from the third to the seventh decade.16
Apolipoprotein A-1 Milano
The amino acid substitution of cysteine for arginine at position 173 has 
the effect of changing the physical property of one of the amphipathic helical 
regions involved in lipid binding and also allows disulphide bonding to other 
proteins. The apolipoprotein A-1 Milano genotype is associated with reduction 
in  high  density  lipoprotein  levels  but  paradoxically  is  protective  against 
atherosclerosis.19
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Apolipoprotein A-11
It has a molecular weight of 17,000 daltons and has 154 amino acids, 
with a structure consisting of two identical monomers joined by a disulphide 
bridge.  Its  inhibition  of  apolipoprotein  A-1  and  lecithin  cholesterol  acyl 
transferase is questionable. It is associated with high density lipoproteins and 
chylomicrons5.
Apolipoprotein AIV     
It  is  secreted  with  chylomicrons  but  transferred  to  high  density 
lipoproteins. The molecular weight is 46,000 daltons. Apolipoprotein A-IV is 
associated  with  the  formation  of  triacylglycerol  rich  lipoprotein.  It  is 
synthesized by the intestine.2
Apolipoprotein B100 : 
It  is  the  main  apolipoprotein  of  low  density,  very  low  density  and 
intermediate density lipoprotein. It is the longest single polypeptide with 4536 
aminoacids and molecular weight 5,50,000 daltons.2
Apolipoprotein B48: 
Apolipoprotein  B48  is  synthesized  from  the  same  mRNA  as 
apolipoprotein B100, but due to RNA editing mechanism a smaller polypeptide 
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is  formed.  Chylomicron  and  chylomicron  remnants  contain  this 
apolipoprotein.2
Apolipoprotein  CI  CII  CIII  are  smaller  polypeptides  freely  transferable 
between  several  different  lipoproteins.  Apolipoprotein  C1  is  a  possible 
activator of lecithin cholesterol acyl transferase and Apolipoprotein CII is an 
activator of lipoprotein lipase. Apolipoprotein CIII may inhibit the activation of 
lipoprotein lipase by Apolipoprotein CII.
Apolipoprotein E is an arginine rich apolipoprotein found in very low density 
lipoprotein and acts as a ligand for chylomicron remnant receptor in liver and 
low density lipoprotein receptor.5
22
METABOLISM IN PREGNANCY
Pregnancy  is  hyperlipidemic  and  glucosuric.  These  physiological 
changes  in  lipid  and  carbohydrate  metabolism  are  accompanied  by  related 
alterations in amino acids. Together they increase the availability of glucose for 
the fetus while the mother utilizes lipids. These metabolic modifications start 
soon after conception, increase and become most marked in the second half of 
pregnancy coinciding with increasing fetal requirements for growth. The uterus 
and placenta also require carbohydrate fat and amino acids for work as well as 
for structure22.     
Carbohydrate Metabolism
Glucose passes freely across the placenta so its increased availability in 
the maternal circulation is of direct benefit to the fetus. Glucose also passes 
freely across the glomerulus, exceeding the tubular threshold, with glycosuria 
detected significantly often in pregnant women. Accompanying the glycosuria 
are other apparent abnormalities like insulin sensitivity increasing in first half 
and  decreasing  in  second  half  of  pregnancy.  This  increased  sensitivity 
stimulates glycogen synthesis and storage, deposition of fat, and transport of 
amino acids into cells.
After 20 weeks of gestation, resistance to the action of insulin develops 
progressively and plasma levels of insulin rise. Likewise, plasma glucose level 
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also increases  with a delay in return to fasting level in Glucose Tolerance Test 
(GTT). Fasting plasma insulin levels reach their maximum at around 32 weeks 
but the decrease in sensitivity to its action persists until delivery. This reduces 
maternal  utilisation  of  glucose  and  induces  glycogenolysis  and 
gluconeogenesis, as well as the utilisation of lipids as energy sources. This can 
cause rapid development of ketosis during labour.22 
Insulin resistance maybe a consequence of increased levels of human 
placental  lactogen,  oestrogen and progesterone.  Oestrogen increases  cortisol 
binding globulin which stimulates the adrenal to produce sufficient cortisol to 
produce insulin resistance. Progesterone  increases  the  level  of  serum insulin 
without  altering  the  concentration  of  glucose.  Human  placental  lactogen 
stimulates insulin release and inhibits glucose uptake22.
Amino  acids  :  The  plasma concentration  of  most  amino  acids  usually 
glucogenic amino acids like alanine falls during pregnancy. This may be due to 
transport across the placenta and increased utilisation of amino acids by the 
mother for gluconeogenesis.
Proteins: The concentration of proteins in the maternal serum falls markedly, 
by 20 weeks of gestation. The total protein concentration falls from 7.0g to 
6.0g per 100ml. Most of this is due to fall in serum albumin from 3.5g to 2.5g 
per 100ml, globulins may even rise by 0.2g per 100ml. The fall in albumin 
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concentration reduces the colloid osmotic pressure in the plasma, which is one 
of the factors predisposing to edema in pregnancy.
Lipid Metabolism in Pregnancy
Normal pregnancy is hyperlipaemic. All lipid levels are raised but the 
greatest increase is in triglyceride rich components. Plasma concentrations tend 
to underestimate the magnitude of the total increase because plasma volume 
doubles during pregnancy.
Total plasma cholesterol  falls by 5% early in pregnancy, reaching its 
lowest point at 6-8 weeks. Following the initial fall there is a progressive rise to 
term. Total cholesterol increases by 24-206%, in very low density lipoproteins 
by 36% and in low density lipoproteins by 50 -90%. High density lipoproteins 
is raised by 10-23% at term, having risen to 30% in mid gestation and fallen. 
The  most  prominent  change  was  a  2.7  fold  increase  in  triglycerides  with 
concentrations raised by 90-570% at term22,24. 
Two mechanisms specific for pregnancy seem to be responsible for this 
phenomenon.  First  elevated  estrogen  levels  during  gestation  result  in  an 
increased hepatic synthesis of triglyceride rich very low density lipoprotein. 
Secondly, removal of lipoprotein triglycerides is reduced due to low activities 
of  lipoprotein  lipase,  and  hepatic  triglyceride  lipase,  the  effect  being  more 
striking for hepatic lipase than for lipoprotein lipase. The abundance of very 
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low  density  lipoprotein  triglycerides  drives  an  accelerated  transfer  of 
triglycerides to lipoproteins of higher density by the cholesteryl ester transfer 
protein. Thus the reduced hepatic lipase activity appears to be responsible for 
the shift of high density subclasses toward larger triglyceride rich and more 
buoyant species in late gestation. The low density lipoproteins also become 
enriched in triglycerides, but these particles become smaller and denser27.
Maternal low density lipoprotein cholesterol is an important precursor of 
placental steroids (estradiol and progesterone). During pregnancy the placenta 
secretes a polypeptide hormone placental lactogen and two steroid hormones 
estradiol and progesterone. Placental lactogen stimulates lipolysis in adipose 
tissue and the steroid hormones induce an insulin resistant state. Thus in the 
post prandial state, pregnant women enter the starved state more rapidly than 
do nonpregnant women. This results from increased consumption of glucose 
and amino acids by the fetus. Plasma glucose, amino acids and insulin levels 
falls  rapidly  and  glucagon  and  placental  lactogen  levels  rise  and  stimulate 
lipolysis and ketogenesis. The consumption of glucose and amino acids by the 
fetus may be great enough to cause maternal hypoglycemia. On the other hand, 
in the fed state pregnant women have increased levels of insulin and glucose 
and demonstrated resistance to exogenous insulin30.    
Long chain polyunsaturated fatty acids (LCPUFA) circulate in maternal 
plasma, associated to lipoprotein triglycerides, and in a minor proportion in the 
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form  of  free  fatty  acids.  Despite  the  lack  of  a  direct  placental  transfer  of 
triglycerides, diffusion of their fatty acids to the fetus is ensured by means of 
lipoprotein  receptors,  lipoprotein  lipase  activity  and  intracellular  lipase 
activities in the placenta. Maternal plasma free fatty acids are also an important 
source of long chain polyunsaturated fatty acids to the fetus, and their placental 
uptake  occurs  via  a  selective  process  of  facilitated  membrane  translocation 
involving  a  plasma  membrane  fatty  acid  binding  protein.  This  mechanism 
together  with  a  selective  cellular  metabolism  determine  the  actual  rate  of 
placental transfer and its selectivity, resulting even in an enrichment of certain 
long  chain  polyunsaturated  fatty  acids,  in  fetal  circulation  as  compared  to 
maternal. The degree to which the fetus is capable of fatty acid desaturation 
and  elongation  is  not  clear,  although  both  term  and  preterm  infants  can 
synthesise long chain poly unsaturated fatty acids from parental essential fatty 
acids. Therefore the fetus which receives the nutritional supply from the mother 
has a growth proportional to the nutritional state of the mother. The nutritional 
supply to the fetus from the mother is illustrated in Fig.4.
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After delivery, plasma levels of lipids return to normal but this may take 
6 months for some lipids and is affected by whether or not the mother breast 
feeds and by the use of oral contraceptives22,35.
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Apolipoprotein A-1 in Pregnancy          
Apolipoprotein  A-1  is  the  major  protein  component  of  High  density 
lipoprotein and comprises approximately 70% of the total protein mass in this 
lipoprotein. The high density lipoprotein concentrations in normal pregnancies 
are  closely  related  to  circulating  progesterone  and  oestrogen,  and  to  the 
pregnancy period, in which they are determined. The high density lipoprotein 
concentration  increases  through  a  rise  in  apolipoprotein  A-1  synthesised 
predominantly in the liver when oestrogen levels are raised.
Apolipoprotein A-1 levels were significantly elevated in the second and 
third trimesters, reaching their highest levels in the second trimester followed 
by  a  fall  after  33  weeks.  Apolipoprotein  A-II  also  increases  but  it  is  not 
significant. Apolipoprotein B100 increases throughout pregnancy36.   
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INTRAUTERINE GROWTH OF FETUS
Human fetal growth is characterized by sequential patterns of tissue and 
organ growth, differentiation, and maturation that are determined by maternal 
provision of substrate and fetal growth potential governed by the genome.
Fetal growth has been divided into three consecutive cell growth phases
First 16 weeks: phase of hyperplasia characterized by rapid increase in 
cell number
16 – 32 weeks : Cellular hyperplasia and hypertrophy
> 32 weeks : Cellular hypertrophy
During  the  third  phase,  most  fetal  fat  and glycogen deposition takes 
place. The corresponding fetal growth rates during these cell growth phases are 
from 5g/day at 15weeks, 15 to 20g/day at 24 weeks and 30to 35g/day at 34 
weeks38.  
Under  ideal  conditions  sufficient  amounts  of  maternal  nutrients  are 
provided across utero placental circulation which functions efficiently to meet 
the  demands of  the  growing fetus.  An appropriate  hormonal  and endocrine 
milieu  for  both  mother  and  fetus  enables  optimal  growth,  with  balanced 
interaction of many factors. This allows normal development and maturation 
and  ultimately  a  smooth  transition  from  intrauterine  to  extrauterine  life. 
Metabolic  shift  occurs  in  virtually  all  maternal  nutrients  in  pregnancy.  The 
placenta and the uteroplacental blood flow play a key role in regulation and 
delivery of fuel to the fetus. 40
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INTRAUTERINE GROWTH RESTRICTION
According to World Health Organisation low birth weight is defined as 
2500 grams or less and prematurity as birth at 37 weeks or less.  Low birth 
weight defined as less than 2500 grams has been modified to describe very low 
birth weight infants weighing 1500 grams or less, extremely low birth weight 
those who weigh 1000 grams or less. Nowadays the term restriction has largely 
replaced retardation as the latter may erroneously convey mental delay rather 
than only the intended suboptimal fetal growth 38.   
Risk  factors  of  intrauterine  growth  restriction  are  constitutionally  small 
mothers,  poor  maternal  weight  gain,  social  deprivation,  fetal  infections, 
congenital  malformations,  chromosomal  abnormalities,  chemical  teratogens, 
vascular disease, chronic renal disease, chronic hypoxia, maternal anaemia, and 
placental and cord abnormalities.
Screening and identification of Intrauterine growth restriction
 These include
 Early establishment of gestational age
 Monitoring maternal weight gain
 Uterine  fundal  height  between 18  and 30  weeks.  The  uterine  fundal 
height in centimeters conincides with weeks of gestation.
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 Ultrasonic  measurement:  Routine  ultrasound  screening  at  16  to  20 
weeks to rule out visible anomalies, and follow up at 32 to 34 weeks to 
evaluate fetal growth.
 Doppler velocimetry – abnormal umbilical artery Doppler velocimetry 
characterised  by  absent  or  reversed  end  diastolic  flow  signifying 
increased  impedance  has  been  uniquely  associated  with  fetal  growth 
restriction.
Growth appears to be the best indicator of long term fetal well being and 
might be associated with development of abnormal states later in life. Distinct 
from their  appropriately  grown counterparts,  growth  restricted  fetuses  have 
physiologic  characteristics  that  are  believed  to  alter  permanently  the 
development  and  metabolic  function  of  organs.  In  addition  to  increased 
morbidity and mortality, growth restriction has been associated neonatally with 
hypoglycemia,  hypocalcemia,  polycythemia  and  thrombocytopenia. 
Hypoinsulinemia  decreased  thyrotropin  levels,  and  diminished  insulin  like 
growth factor-1 have been described in small for gestational age infants.38 
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APOLIPOPROTEIN A-1 AND LIPOPROTEINS IN 
INTRAUTERINE GROWTH RESTRICTION
Pregnancies having intrauterine growth restriction are associated with an 
abnormal lipid profile, with significant decreases in levels of serum cholesterol, 
serum triglyceride, low density lipoprotein and high density lipoprotein when 
compared with normal pregnancies. Although high density lipoprotein values 
were  not  statistically  different  in  normal  when  compared  with  pregnancies 
complicated with intrauterine growth restriction, apolipoprotein A-1 level was 
significantly lower in women with intrauterine growth restricted pregnancies.36
Studies from different areas have shown that indices of fetal  growth, 
such as birth weight are inversely associated with cardiovascular morbidity and 
mortality in men and women in adult life. Although the mechanisms are not 
known it  has been suggested that abnormalities in the metabolism of serum 
lipids  may,  in  part,  explain  these  associations.  Several  recent  studies  have 
demonstrated that total cholesterol, low density lipoprotein, and apolipoprotein 
B, known risk factors for cardiovascular disease are inversely related to size. In 
addition,  there  is  some evidence  that  small  size  at  birth  is  associated  with 
decreased levels of high density lipoprotein cholesterol and apolipoprotein A-1. 
These  associations  have  been  attributed  to  a  programmed  response  to 
intrauterine malnutrition that induces permanent changes in the structure and 
function of organs, which cause an atherogenic lipid profile in adult life. This 
theory is supported by a study demonstrating that exposure to the Dutch famine 
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in utero influenced lipid levels in later life. The alternative view is that genetic 
factors  influencing  both  birth  weight  and  lipid  profile  could  explain  the 
relationships between these two factors. Genetic factors play an important role 
in the determination of serum lipids,  and to a lesser extent,  birth weight.  It 
could  be  proposed  that  the  genotype  responsible  for  an  altherogenic  lipid 
profile might itself cause restricted fetal growth in utero.41 
The  concurrent  decrease  in  apolipoprotein  A-1  and  increase  in 
apolipoprotein  B  in  pregnancies  with  intrauterine  growth  restriction  could 
partly explain the viscosity changes that occur in this complicated pregnancy. 
The affinity of both apolipoprotein B and plasminogen for the same endothelial 
receptors  leading to competitive inhibition of fibrinolysis,  could explain the 
increase  in  plasma  viscosity  observed  in  the  case  of  intrauterine  growth 
restriction36.     
Apolipoprotein B increases throughout pregnancy both in normal and in 
pregnancies  with  restricted  fetal  growth.  Apolipoprotein  A-1  shows  a  non 
significant decrease after 33 weeks in normal pregnancies but in women with 
intrauterine growth restriction a decline to pregestational  levels  is  observed. 
Haemorrheological modifications in the intrauterine growth restricted group are 
in part secondary to changes in high density lipoprotein metabolism, mainly 
serum  levels  of  Apolipoprotein  A-1.  Along  with  thorough  clinical  assays, 
changes in Apolipoprotein A-1 and more specifically high density lipoprotein / 
apolipoprotein  A-1  ratio  could  be  a  good  marker  of  intrauterine  growth 
restricted pregnancies.41,42      
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AIM OF THE STUDY
A review of literature on previous studies in normal pregnancies and 
pregnancies with intrauterine growth restriction revealed variations in the lipid 
profile between the two groups. Among the lipid parameters, Apolipoprotein 
A-1  was  significantly  different  in  the  pregnancies  with  intrauterine  growth 
restriction when compared to normal pregnancies. However, these studies were 
not able to clearly define the role of lipid metabolism in the pathogenesis of 
intrauterine growth restriction, and there is still a dearth of literature on this 
aspect. So the present study was undertaken with the following aim. 
1. To determine total  cholesterol,  triglycerides,  high density  lipoprotein, 
low density lipoprotein, and very low density lipoprotein in healthy non 
pregnant  women,  in  normal  pregnancies  and  pregnancies  with 
intrauterine growth restriction. 
2. To establish the serum level of Apolipoprotein A-1 in apparently normal 
healthy non pregnant women of the child bearing age, in normal healthy 
pregnant  women  and  in  pregnant  women  with  intrauterine  growth 
restriction  with  a  view  to  assess  the  role  of  Apolipoprotein  A-1  in 
intrauterine growth restriction.
3. To determine  whether  a  cut  off  level  of  Apolipoprotein  A-1  can  be 
established between normal pregnancy and pregnancy with intrauterine 
growth restriction.
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MATERIALS AND METHODS
The study was conducted on 80 female individuals  in  the  age group 
20-35 years.   Among them 20 healthy  non  pregnant  women selected  from 
friends and relatives formed the control group.  The remaining 60 women were 
selected from those admitted to Government Kasthurbha Gandhi Hospital for 
Women and Children, Triplicane, Chennai – 5.  Among them 20 women with 
gestational  age  greater  than  35  weeks,  formed  the  study  group  of  normal 
pregnancies  with  ultrasound findings  corresponding to  their  gestational  age. 
The remaining 40 women with similar gestational age formed the study group 
of pregnancies with intrauterine growth restriction.
The  pregnancies  with  intrauterine  growth  restriction  group  had 
ultrasound  findings  showing  discrepancy  between  the  gestational  age  and 
actual  size of the uterus.  Pregnancies with pregnancy induced hypertension, 
maternal  diabetes,  fetal  congenital  anomalies  or  malformations,  maternal 
hepatic / renal / thyroid diseases and any other confounding factor which may 
affect fetal nutrition and growth were excluded from the study. 
BLOOD COLLECTION 
About 8ml of blood was collected after an overnight fast. The blood was 
allowed to clot and the serum separated. After centrifugation clear serum was 
obtained.  The  levels  of  serum  cholesterol,  triglycerides,  and  high  density 
lipoprotein  cholesterol  were  measured  within  3  hours  of  blood  collection. 
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About 1 ml of serum was stored in eppendorfs at – 200C for the estimation of 
apolipoprotein A-1.
LIPID ASSAYS 
1. TRIGLYCERIDES
Serum triglycerides  were  measured  using  the  enzymatic  colorimetric 
method.
Kit used - Autopak
PRINCIPLE     Enzymatic determination of triglycerides was done based on 
the following reactions
Triglycerides + H2O LIPOPROTEIN LIPASE Glycerol + Fatty acid
Glycerol + ATP GLYCEROL KINASE    Glycerol 3 phosphate +ADP
Glycerol. 3 phosphate+O2 GPO Dihydroxy acetone phosphate + H2O2 
2H2O2 + 4-Aminoantipyrine + ADPS PEROXIDASE Red quinone +4H2O
GPO = Glycerol 3 phosphate oxidase. 
ADPS = N Ethyl – N- Sulfopropyl– n- ansidine
The  intensity  of  the  coloured  complex  produced  which  was  directly 
proportional to concentration of triglycerides was measured at 546nm.
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REAGENTS  
Reagent 1(Enzymes / Chromogen) 
Lipoprotein Lipase - 1100 U/L
Glycerol Kinase - 800 U/L
Glycerol 3 phosphate oxidase - 5000 U/L
Peroxidase - 350 U/L
4-Aminoantipyrine - 0.7 mmol/L
ATP - 0.3 mmol/L
Reagent 1A  (Buffer);
Pipes buffer, ph 7.50 - 50 mmol/L
ADPS - 1mmol/L
Magnesium salt - 15 mmol/L
Standard 
        Triglycerides 200mg/dl 
Preparation of working reagent
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The contents of one bottle of Reagent 1 was mixed with one bottle of 
Reagent 1A and mixed by gentle swirling. 
Procedure   
1ml of working reagent and 10µl of sample / standard were mixed and 
incubated for 5 minutes at 370C. The absorbance was measured at 546 nm.
Blank Standard Sample
Working Reagent 1000 µl 1000 µl 1000 µl
Distilled water 10 µl - -
Standard - 10 µl -
Sample - - 10 µl
Calculation  
Concentration of triglycerides =  dardtanSOD
SampleOD
 x 200
Linearity upto 1000mg / dl
Reference range Male  : 60 – 165 mg  / dl 
Female : 40-140 mg / dl 
2. ESTIMATION OF CHOLESTEROL – TOTAL
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Serum  cholesterol  was  estimated  using  the  enzymatic  cholesterol 
oxidase method.
Kit used - Autopak
Principle 
Enzymatic  determination  of  cholesterol  was  done  based  on  the  following 
reactions
Cholesterol Ester +H2O CHOLESTEROL ESTERASE Cholesterol+Fatty acids 
Cholesterol + O2 CHOLESTEROL OXIDASE Cholestenone + H2O2
2H2O2 + Phenol + 4 Aminoantipyrine PEROXIDASE Red  quinone + 4H2O 
The  intensity  of  coloured  complex  produced  which  was  directly 
proportional to concentration of cholesterol content  was measured  at 505  nm.
REAGENTS
Reagent 1 (Enzymes / Chromogen) 
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Cholesterol Esterase - 200 U/L
Cholesterol Oxidase - 250 U/L
Peroxidase - 1000 U/L
4-Amino antipyrine - 0.5 mmol/L
Reagent 1A (Buffer) 
Pipes buffer, pH 6.90 - 50 mmol/L
Phenol - 24 mmol/L
Soduim cholate - 0.5 mmol/L
Standard – cholesterol standard 200mg / dl 
Preparation of working reagent
Reagent 1 was dissolved in 50ml of Reagent 1A and mixed gently, and 
stored in amber coloured bottles at 2-80 C
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Procedure 
1ml of working reagent and 10µl of sample / standard were mixed and 
incubated for 10 min at 370C. The absorbance was measured at 505mn against a reagent blank. 
Blank Standard Sample 
Working Reagent 1000µl 1000 µl 1000 µl
Standard - 10 µl -
Sample - - 10 µl
Calculation 
Cholesterol concentration mg /d1 = 200xdardtansofAbsorbance
testofAbsorbance
Linearity upto 500mg / dl
Reference range depends on age, sex, diet, race and geographical 
location. Serum level 150 – 200 mg /dl
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3. HDL CHOLESTEROL
Serum  HDL  cholesterol  was  estimated  using  the  phosphotungstate 
method. 
Kit Used - Autopak
Principle – PHOSPHOTUNGSTIC ACID METHOD
Chylomicrons, VLDL and LDL fractions in serum were separated from 
HDL  by  precipitating  with  phosphotungstic  acid  and  magnesium  chloride. 
After centrifugation, the cholesterol in the HDL fraction which remained in the 
supernatant was assayed with cholesterol enzymatic method 
REAGENTS 
Reagent 1 (Enzymes / Chromogen) 
Cholesterol esterase - 200 U/L
Cholesterol oxidase - 250 U/L
Peroxidase - 1000 U/L
4 Aminoantipyrine   -         0.5mmol/L
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Reagent 1- A (Buffer) 
Pipes buffer. pH 6.90 - 50 mmol/L
Phenol - 24 mmol/L
Sodium Cholate - 0.5 mmol/L
Reagent 2 (Precipitating Reagent) 
Phosphotungstic acid - 2.4 mmol/L
Magnesium chloride - 39 mmol/L
Standard HDL cholesterol 50mg / dl
PROCEDURE  
Precipitation 
200µl  of  the  sample  was  mixed  with  200µl  of  the  precipitating  
reagent 2, allowed to stand for 10min at room temperature and then centrifuged 
at 4000 rpm for 10min to obtain a clear supernatant. The supernatant was used 
to determine the concentration of HDL cholesterol in the sample. 
Assay procedure 
1ml  of  cholesterol  working  reagent  was  mixed  with  20µl  of  the 
supernatant / standard and incubated for 5 min at 370C. The absorbance was 
measured at 500 nm against a reagent blank. 
44
Blank Standard Test 
Reconstituted  reagent 1ml 1ml 1ml
Standard - 20ul -
Supernatant - - 20ul 
 
Calculation 
HDL cholesterol  = dardtanSOD
SampleOD
 x conc. standard 
The standard of 50mg /dl is fed as 100mg /dl to account for the dilution 
of the sample in the precipitation step.
Reference Range 
In males : 30 – 65 mg/dl
In females : 35 – 80 mg/dl  
4. VLDL cholesterol and LDL cholesterol  
VLDL cholesterol and LDL cholesterol were calculated using the 
FRIEDEWALD EQUATION 
(LDL cholesterol) = (Total cholesterol)-  (HDL Cholesterol)  - Triglyceride/5
VLDL cholesterol =  Triglyceride/5 
As per the reference range of the Autopak Kit utilised for TC and HDL 
cholesterol this should vary from VLDL : Males 12 - 33 mg / dl; Females 8 - 
28 mg / dl. LDL : Male  108 - 162 mg / dl; Females 107 - 152 mg / dl.
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APOLIPOPROTEIN A-1
Turbidimetric Test 
Kit used - Spinreact
Principle 
Anti Apo A-1 antibodies when mixed with samples containing Apo A-1, 
formed insoluble complexes. These complexes caused an absorbance change 
dependent upon the Apo A-1 concentration of the patients sample, which was 
quantified by comparison from a calibrator of known Apo A-1 concentration. 
Reagents. 
Reagent (R1). Diluent Tris buffer 100mmol/L 
Polyethylene glycol 4000 
pH 7.2 sodium azide 0.95g/L
Reagent (R2) Antibody Goat serum, anti human Apo A-1, tris 100 mmol /L
pH 7.2 sodium azide 0.95g/L
Preparation of working reagent
The working reagent was prepared by diluting antiserum Apo A-1 (R2) 
1:41 with buffer solution (R1) 
Samples  were diluted 1:21 with saline solution (NaCl 0.9%). 
Apo CAL calibrator dilutions in NaCl 9g/L as diluent was prepared. 
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Procedure 
Spectrophotometer semi autoanalyser. 
Wavelength 600nm
Temperature 370C
Cuvette light path 1 cm
Measurement 
1ml of the working reagent and 20µl of the diluted sample / calibrator 
dilution was mixed and incubated at 370C for 10 minutes. The absorbance was 
read. at 600nm. 
Blank Sample 
Working Reagent 1.0ml 1.0 ml
Saline Solution (0.9%) 20 µl -
 Sample / Calibrator - 20 µl 
Calculation 
A calibration curve was plotted with the absorbance and the Apo A-1 
concentration of each calibrator dilution. Apo A-1 concentration in the sample 
was calculated by interpolation of its aborbance in the calibration curve.
Linearity - 600 mg/dl
Reference range - Between 122-161 mg/dl.
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RESULTS
The  level  of  serum  apolipoprotein  A-1  and  other  biochemical 
parameters namely serum total cholesterol,  serum triglycerides,  high density 
lipoprotein,  very  low density  lipoprotein and low density  lipoprotein in  the 
control and study groups are tabulated in tables I  to III Table I consists of the 
biochemical  levels  in  the  control  group  namely,  the  normal  non  pregnant 
women.  The biochemical  parameters in normal pregnancies are tabulated in 
table II, and the biochemical levels of pregnancies with IUGR are tabulated in 
table III.
The mean and standard deviation for the parameters analysed in each 
group is also given in the respective tables.   The same has been elaborated 
separately in table.IV The mean level of each biochemical  parameter in the 
different  groups  along  with  its  standard  deviation  are  also  shown  as  bar 
diagrams from Chart II to Chart VIIs.
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TABLE – I
Normal non - pregnant women
Sl.
No
Total
Cholesterol
(mg/dl)
TGL
(mg/dl)
VLDL
(mg /dl)
HDL
(mg/dl)
LDL
(mg/dl)
ApoA-1
(mg/dl)
1. 138 100 20 45 73 105.1
2. 122 129 25.8 40 56.2 91.2
3. 187 200 40 40 107 176.7
4. 186 173 34.6 44 107.4 213.3
5. 170 196 39.2 42 88.8 162.1
6. 140 178 35.6 42 62.4 185.7
7. 165 180 36 40 89 131.3
8. 170 190 38 44 88 196.1
9. 122 90 18 40 64 102.6
10. 209 113 22.6 42 144.4 69.3
11. 185 101 20.2 44 120.8 121.7
12. 140 122 24.4 42 73.6 106.2
13. 160 94 18.8 44 97.2 107.7
14. 175 131 26.2 46 102.8 125.0
15. 182 127 25.4 42 114.6 161.7
16. 174 100 20 44 110 220.9
17. 171 93 18.6 38 116.4 124.5
18. 180 98 19.6 44 126.4 115.5
19. 186 101 20.2 40 125.8 67.3
20. 170 126 25.2 36 108.8 95.8
Mean 166.6 132.1 26.4 41.9 98.8 133.9
S.D ± 23.1 ± 38.7 ± 7.7 ± 2.5 ± 24 ± 45.6
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TABLE –II
Normal Pregnant women
Sl.
No
Total
Cholesterol
(mg/dl)
TGL
(mg/dl)
VLDL
(mg /dl)
HDL
(mg/dl)
LDL
(mg/dl)
ApoA-1
(mg/dl)
1. 293 196 39.2 30 179.8 184.6
2. 244 231 42.2 28 169.8 215.4
3. 226 210 42 52 132 229.7
4. 201 119 28.8 34 143.2 187.2
5. 245 257 51.4 32 161.6 263.4
6. 246 323 64.6 48 133.4 328.1
7. 220 198 39.6 40 140.4 117.6
8. 232 405 81 51 100 225.7
9. 155 128 25.6 40 89.4 130.9
10. 207 188 37.6 30 139.4 171.9
11. 291 296 59.2 30 201.8 175.4
12. 234 224 44.8 50 139.2 149.2
13. 253 126 25.2 60 167.8 135.4
14. 204 276 55.2 44 104.8 182.2
15. 280 231 46.2 66 167.8 216
16. 193 321 64.2 42 86.8 169.7
17. 237 190 64.2 46 126.8 127.2
18. 230 234 46.8 62 121.2 176.5
19. 225 246 48 40 137 122.8
20. 220 250 50 50 120 152.7
Mean 231.8 232.4 47.7 42.5 138.1 183.0
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Sl.
No
Total
Cholesterol
(mg/dl)
TGL
(mg/dl)
VLDL
(mg /dl)
HDL
(mg/dl)
LDL
(mg/dl)
ApoA-1
(mg/dl)
S.D ± 32.9 ± 70.6 ± 14.1 ± 12.0 ± 30.3 ± 52.3
TABLE -  III
Pregnancies with IUGR
Sl.
No
Total
Cholesterol
(mg/dl)
TGL
(mg/dl)
VLDL
(mg /dl)
HDL
(mg/dl)
LDL
(mg/dl)
ApoA-1
(mg/dl)
1. 131 248 49.6 32 49.4 76.14
2. 252 246 49.2 44 158.8 130.64
3. 159 372 74.4 30 54.6 165.87
4. 226 237 47.4 33 145.6 120.51
5. 194 135 27 28 139 120.21
6. 174 337 67.4 44 62.6 130.4
7. 249 188 37.6 40 171.4 170.2
8. 122 169 33.8 30 58.2 110.1
9. 192 168 33.6 36 122.4 140.2
10. 216 167 33.4 24 158.6 150.1
11. 168 196 39.2 34 94.8 136.3
12. 162 92 18.4 30 113.8 81.3
13. 167 221 44.2 30 92.8 130.1
14. 173 194 38.8 36 98.2 133.6
15. 277 121 24.2 62 190.8 160.1
16. 232 205 41 50 141 165.9
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Contd . . . 
Sl.
No
Total
Cholesterol
(mg/dl)
TGL
(mg/dl)
VLDL
(mg /dl)
HDL
(mg/dl)
LDL
(mg/dl)
ApoA-1
(mg/dl)
17. 200 159 31.8 56 112.2 170.1
18. 208 176 35.2 46 126.8 90.3
19. 167 156 31.2 44 91.8 100.4
20. 225 287 57.4 24 143.6 170.3
21. 191 116 23.2 48 119.8 139 4
22. 239 229 45.8 32 161.2 170.2
23. 295 175 35 30 230 151.2
24. 235 163 32.6 40 162.4 160.1
25. 367 238 47.6 44 275.4 170.3
26. 179 135 27 45 107 150.5
27. 398 358 71.6 40 286 140
28. 141 70 14 42 85 154.9
29. 167 144 28.8 40 98.2 149.2
30. 195 176 35.2 38 121.8 79.2
31. 202 168 33.6 42 126.4 107.7
32. 178 156 31.2 44 102.8 176.3
33. 212 206 41.2 32 138.8 184.3
34. 187 172 34.4 36 116.6 160.8
35. 193 184 36.8 40 116.2 174.4
36. 186 176 35.2 38 112.8 121.1
37. 194 190 38 40 116 198.8
38. 201 186 37.2 36 127.8 82.3
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Sl.
No
Total
Cholesterol
(mg/dl)
TGL
(mg/dl)
VLDL
(mg /dl)
HDL
(mg/dl)
LDL
(mg/dl)
ApoA-1
(mg/dl)
39. 188 174 34.8 38 115.2 148.1
40. 197 188 37.6 34 119.4 162.0
Mean 205.9 192.7 38.9 38.3 129.1 140.8
SD ± 54.5 ± 62.9 ± 12.6 ± 7.9 ± 50.2 ± 31.3
Table  - IV
Mean and Standard deviation of the biochemical parameters 
in the different groups
Variables Normal Nonpregnant 
Normal 
Pregnancies Pregnancy with IUGR 
TC mg/dl 166.6 ± 23.1 231.8 ± 32.9 205.9 ±  54.5
TGL mg/dl 132.1 ± 38.7 232.4 ± 70.6 192. 7 ± 62.9
VLDL mg/dl 26.4 ± 7.7 47.7 ± 14.1 38.9 ± 12.6
HDL mg/dl 41.9 ± 2.5 42.5 ± 12.0 38.3 ± 7.9
LDL mg/dl 98.8 ± 24.0 138.1 ± 30.3 129.1 ± 50.2
Apo A-1, mg / dl 133.9 ± 45.6 183.0 ± 52.3 140 .8 ± 31.3
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DISCUSSION
On scrutinisation of the mean obtained for the lipid parameters in the 
control group (tables I) namely 166.6 ± 23.1mg/dl for total cholesterol, 132.1 ± 
38.7 mg / dl for triglycerides, 26.4 ± 7.7 mg/dl for VLDL, 41.9 ± 2.5 mg/dl for 
HDL  and  98.8±24.0  mg/dl  for  LDL,  it  is  seen  that  total  cholesterol, 
triglycerides and HDL fall well within the reference range of the kit method 
employed for  their  analysis.  VLDL and LDL mean correlate  well  with  the 
reference range given in standard reference books. 
Apolipoprotein  A-1  whose  mean  level  is  133.9  ±  45.6  mg/dl  in  the 
above group is well within the reference range of 122 to 166mg/dl of the kit 
method employed for its analysis, and that of Dr.Nobert Tietz who has quoted a 
reference range of  130 to  160 mg/dl for  females.   As the mean for  all  the 
parameters in the control group, correlate well with the reference range of the 
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kit method employed for their analysis, or that quoted in standard books they 
are found to be valid and accepted as reference range for the present study.
The mean levels of lipid parameters in normal pregnant women (table 
II) and those with IUGR (table III) correlate well with that given by Dabi DR43. 
Apolipoprotein A-1 in both the groups is lower to that obtained by Munoz et 
al36. To find out whether the mean values for the different parameters in normal 
pregnancies,  and pregnancies  with IUGR, varied  from that  of  the  reference 
range obtained for the study, the latter means are compared with that of the 
former in tables V and VI respectively.  The ‘p’ value on their comparison has 
been  obtained  by  using  the  students  ‘t’  test  and  the  same  along  with  its 
corresponding statistical significance has been given in the respective tables.
Table - V
Comparison of the levels of the biochemical parameters in 
normal pregnancies with reference range
Group
TC 
mg/dl
TGL 
mg/dl
VLDL 
mg/dl
HDL 
mg/dl
LDL 
mg/dl
Apo A-1 
mg/dl
Non Pregnant 
Women
166.6 
± 23.1
132.1 
± 38.7
26.4 ± 
7.7
41.9 ± 
2.5
98.8 ± 
24.0
133.9 ± 
45.6
Normal 
Pregnancy 
231.8 
± 32.9
232.4 
± 70.6
47.7 
± 14.1
42.5 ± 
12.0
138.1 ± 
30.3
183.0 ± 
52.0
p value 0.001 0.001 0.001 0.83 0.001 0.003
Significance ↑ HS HS ↑ HS ↑ NS HS ↑ MS ↑
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From table V it is clear that all the lipid parameters in normal pregnant 
women except HDLc are greatly elevated from their reference range resulting 
in high significance (P value 0.001).  The absence of any statistical significance 
for HDLc, can be attributed to the brunt of increase in total cholesterol being 
shared only by, VLDLc and LDLc.  As VLDLc is  a component of VLDL, 
which is transporting endogenous triglycerides from liver to tissues, and on its 
enroute the triglyceride is hydrolysed by lipoprotein lipase; the released free 
fatty acids is taken up by tissues1. In pregnancy, this free fatty acids also goes 
to the fetus.  Since the free fatty acids that supplies the fetus originates from 
VLDL it  is  probably  the  reason for  the  increase  of  this  lipoprotein  and its 
cholesterol  fraction.  LDL which  is  formed  from  VLDL naturally  increases 
leading to the increase of its fraction LDLc.
There  is  absence  of  any  statistical  significance  for  HDL as  its  main 
function is only reverse cholesterol transport, and thereby probably not a source 
of fatty acids to the fetus.  Apolipoprotein A1 level of  183.0  mg / dl in normal 
pregnant  women,  though higher  than the reference range of  the kit  method 
employed is much lower than that of 263  mg / dl obtained by A. Munozetal in 
a similar group36.  This can probably be attributed to the racial variation and to 
the  lower  nutritional  status  of  the  women coming to  general  hospital.   As 
reviewed in literature the increase in apolipoprotein A-1 can be attributed to 
HDL metabolism41,42.
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The following explanation corroborate well to the results  obtained in 
the  study.  The  changes  in  lipid  levels  during  pregnancy  result  from  the 
metabolic adaptation of the mother, mobilisation of fat deposits, the increase in 
free  fatty  acids  and  the  relationship  between  circulating  progesterone  and 
oestrogen suggesting that these hormones are responsible for the lipid change 
observed.   The increase  in  triglyceride  concentration in  normal  pregnancies 
indicates a progressive increase in the supply of free fatty acids to the fetus 
during  pregnancy.  Normal  fetal  development  needs  the  availability  of  both 
essential fatty acids and long chain poly unsaturated fatty acids, thus indicating 
a  relationship  between  nutritional  status  of  the  mother  during  gestation  as 
reflected by her lipid profile and fetal growth. 
Table - VI
Comparison of the levels of the biochemical parameters in 
pregnancies with IUGR with reference range.
Group TC mg/dl
TGL 
mg/dl
VLDL 
mg/dl
HDL 
mg/dl
LDL 
mg/dl
Apo A-1 
mg/dl
Non Pregnant 
Women
166.6 
± 23.1
132.1 
± 38.7
26.4 
± 7.7
41.9 
± 2.5
98.8 
± 24.0
133.9 
± 45.6
Pregnancies 
with IUGR
205.9 
± 54.5
192.7 
± 62.9
38.9 
± 12.6
38.3 
± 7.9
129.1 
± 50.2
140.8 
± 31.3
p value 0.003 0.001 0.001 0.05 0.01 0.49
Significance MS ↑ HS ↑ HS ↑ S↓ S↑ NS
In table VI where the group of pregnancies with IUGR is compared with 
non pregnant women,  triglycerides and VLDLc are greatly increased giving 
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rise  statistically  to  high  significance  (p<0.001).  On  the  other  hand  total 
cholesterol  shows  only  a  moderately  significant  increase  unlike  that  in  the 
previous table. This can be due to more of triglyceride synthesis in comparison 
to cholesterol. The increase in triglyceride and VLDLc can be attributed by the 
same explanation, as given for the increase in triglyceride in the previous table 
(table  V).  It  can  be  said  that  the  brunt  of  the  moderate  increase  of  total 
cholesterol is borne by VLDLc than LDLc which shows only a mere significant 
increase.  Apolipoprotein  A-1  unlike  in  previous  table  does  not  show  any 
significant  increase.  This  is  reassured  by  a  significant  decrease  of  HDLc a 
component of HDL.
It is possible that the lower concentrations of serum cholesterol, serum 
triglycerides, VLDLc, and LDLc in the group of pregnancies with IUGR may 
have decreased the availability  of glycerol,  long chain polyunsaturated fatty 
acids and essential fatty acids to the fetuses of the above group of mothers, 
ultimately leading to  intrauterine  growth restriction.  Studies  have suggested 
that deficiencies in essential fatty acids might be present in growth restricted 
fetuses44.  Infusion  of  essential  fatty  acids  to  women  with  intrauterine  fetal 
growth restriction have produced a marked gain in fetal biparietal diameter and 
estimated weight39.
Table - VII
Comparison of the levels of the biochemical parameters in 
pregnancies with IUGR with normal pregnancies.
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Group TC mg/dl
TGL 
mg/dl
VLDL 
mg/dl
HDL 
mg/dl
LDL 
mg/dl
Apo A-1 
mg/dl
Normal 
Pregnancies 
231.8 
± 32.9
232.4 
± 70.6
47.7 
± 14.1
42.5 
± 12.0
1381 
± 30.3
183.0 
± 52.3
Pregnancies 
with IUGR
205.9 
± 54.5
192.7 
± 62.9
38.9 
± 12.6
38.3 
± 7.9
129.1
± 50.2
140.8
± 31.3
p value 0.03 0.03 0.01 0.11 0.47 0.001
Significance S↓ S↓ S↓ NS NS HS ↓
From table VII where the levels  in pregnant women with IUGR and 
normal pregnant women are compared, it is clear that the elevation of the lipid 
parameters namely total cholesterol, triglyceride and VLDLc is more in normal 
pregnant   women than the  group with IUGR.  Hence the above three lipid 
parameter levels are significantly lower (p value 0.03) in the group with IUGR, 
to that in normal pregnant group.  There is absence of any significant variation 
in HDLc and LDLc.   This  can be attributed because these two lipoproteins 
probably are not a source of free fatty acids to the fetus.
Apolipoprotein A-1 in the group of pregnant women with IUGR is much 
lower than its normal counterpart giving rise statistically to a highly significant 
lower p value.  The actual levels of apolipoprotein A-1 in the two groups with 
the obtained significance is elaborated below in table VIII
Table - VIII
Apolipoprotein A-1 levels in normal pregnancies 
and pregnancies with IUGR
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Variable Normal Pregnancies
Pregnancies 
with IUGR p value Significance
Apo A-1 mg/
dl
183.0 ± 52.3 140.8 ± 31.3 0.001 HS ↓
This  finding  correlates  with  the  study  of  A.  Munoz  and  J.  Uberos 
conducted at the University of Granada Hospital, Spain, except for the fact that 
the level of significance is higher in this study.  As this is the only biochemical 
parameter which varies statistically by high significance when the two groups 
of pregnant women are compared, it indicates that the absence of elevation in 
apolipoprotein A-1 level during pregnancy can be a prime contributing factor 
in IUGR.  The ratio of HDL / APO A-1 in the two groups of pregnancies is 
elaborated in the following table IX.
Table  - IX
Ratio of HDL/ApoA-1in normal pregnancies and pregnancies with IUGR.
Group HDL mg/dl Apo A - 1 mg/dl HDL/Apo A-1
Normal Pregnancies 42.5± 12.0 183.0 ± 52.3 0.25 ± 0.09
Pregnancies with 
IUGR
38.3 ± 7.9 140.8 ± 31.3 0.28 ± 0.08
p value 0.11 0.001 0.18
Significance NS HS ↓ NS
The table confirms that determination of the ratio is of no added value in 
this study unlike that of Munoz et al 36.
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According to Jeffrey N. Jones the lipid profile of the intrauterine growth 
restricted  fetuses  indicated  markedly  diminished  fetal  liver  derived 
apolipoprotein  A-1  levels  and  decreased  absolute  total  lipid  levels,  but 
triglycerides were elevated and free fatty acids lowered.  These alternations are 
consistent  with an inability to hydrolyse circulating triglycerides,  leading to 
diminished peripheral  adipose deposition.   The lipid values  in  these fetuses 
indicated  a  diminished  ability  to  deposit  serum  triglycerides  in  sufficient 
amounts to provide adipose stores, diminished levels of free fatty acids and 
impaired formation or secretion of apolipoprotein A-1 all of which are critical 
in the transition to neonatal life.
According  to  A.  Munoz,  haemorrheological  modifications  in  growth 
restricted  pregnancies  are  partly  secondary  to  changes  in  high  density 
lipoprotein metabolism mainly levels of Apolipoproteins A-1. The concurrent 
decrease  in  Apolipoproteins  A-1  and  increase  in  Apolipoprotein  B  in 
pregnancies  with  intrauterine  growth  restriction  could  partly  explain  the 
viscosity changes that occur in this complicated pregnancy.  The affinity of 
both Apolipoprotein B and plasminogen for  the same endothelial  receptors, 
leading to competitive inhibition of fibrinolysis could explain the increase in 
plasma  viscosity  observed  in  the  case  of  intrauterine  growth  restriction. 
However, only Apolipoprotein A-1 levels were determined in the present study.
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The alternative view is that genetic factors influencing both birth weight 
and  lipid  profile  could  explain  the  relationship  between  these  two  factors. 
Genetic factors play an important role in the determination of serum lipids, and 
to  a  lesser  extent,  birth  weight.   It  would  be  proposed  that  the  genotype 
responsible for an atherogenic lipid profile might itself cause restricted fetal 
growth in utero.
In  this  study  as  indicated  by  previous  studies  also,  there  was  a 
significant  decrease  in  apolipoprotein  A-1  levels  in  pregnant  women  with 
intrauterine  growth  restriction.  This  finding  consistent  with  a  decrease  in 
apolipoprotein A-1 levels in cord blood of intrauterine growth restricted fetuses 
as  indicated  by  Jefferey  N.  Jones  suggests  that  the  early  detection  of 
apolipoprotein  A-1  in  pregnant  women  would  be  useful  to  identify  those 
mothers at a greater risk for intra uterine growth restriction.
Hence  attempt  has  been  made  in  this  study  to  ascertain  whether 
apolipoprotein A-1 levels can be a useful marker to identify IUGR.  So the 
levels obtained in the two groups of pregnant mothers have been graphically 
represented in Figure 5.  
FIG. 5 
LINE DIAGRAM OF APOLIPOPROTEIN A-1 LEVELS 
IN NORMAL PREGNANCY AND PREGNANCY WITH IUGR
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For the various cut off levels of apolipoprotein A-1 selected from the 
line diagram the sensitivity, specificity, positive predictive value and negative 
predictive value have been ascertained, which have been tabulated in table X.
TABLE - X
SENSITIVITY SPECIFICITY CHART FOR THE DIFFERENT CUT 
OFF LEVELS SELECTED 
Cut off 
Level Sensitivity Specificity
Positive 
predictive value
Negative 
predictive 
value
160 mg/dl 62.5% 65% 78.1% 46.4%
170 mg/dl 77.5% 65% 81.5% 59.0%
176 mg/dl 92.5% 50% 78.7% 76.9%
From  the  table  it  is  clear  that  a  level  of  176  mg  /  dl  of  
apolipoprotein A-1 which has a  sensitivity of 92.5% is the most appropriate 
level to demarcate the two groups.  But as the above level of apolipoprotein 
A-1  has  only  50  %  specificity  its  reliability  in  confirming  IUGR  can  be 
considered only next to ultrasonography in pregnant women.
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CONCLUSION
Among the lipid parameters triglycerides, VLDL and total cholesterol 
were  much  higher  in  normal  pregnancy  compared  to  their  non  pregnant 
counterpart.  In pregnancy with IUGR though the lipid parameters increased 
from the level in non pregnant women they do not reach the levels seen in 
normal pregnancy.
Apolipoprotein A-1 in normal pregnancies is much higher than in non 
pregnant  women,  this  marked  elevation  of  apolipoprotein  A-1  is  absent  in 
pregnant  women  with  IUGR.  Hence  apolipoprotin  A-1  is  a  significant 
biochemical  parameter  in  differentiating  pregnant  women with  IUGR from 
those of normal pregnancy.
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SCOPE FOR FURTHER STUDY
All the subjects in the present study belonged to the third trimester of 
pregnancy. Further advances in this study can be done by estimating the level 
of Apolipoprotein A-1 in all the three trimesters of pregnancy and comparing 
the corresponding changes in serum levels of Apolipoprotein A-1 in both the 
study  and control group.
A complete nutritional assessment of the pregnant women can be done, 
and  the  level  of  Apolipoprotein  A-1  can  be  estimated  before  and  after 
nutritional  supplements  are  given  in  pregnancies  with  ultrasound diagnosed 
intrauterine growth restriction.
Apolipoprotein A - 1 levels can also be estimated in the fetuses to rule 
out any intrauterine growth restriction.
Other biochemical parameters like Apolipoprotein B can be determined 
and its relation to Apolipoprotein A-1can be studied in pregnancies with IUGR.
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ABBREVIATIONS
TC - Total Cholesterol
TGL - Triglycerides
VLDL - Very Low Density Lipo Protein.
HDL - High Density Lipoprotein
LDL - Low Density Lipoprotein
Apo. A-1 - Apolipoprotein A-1
IUGR - Intra Uterine Growth Restriction.
VLDLc - VLDL Cholesterol
LDLc - LDL Cholesterol
HDLc - HDL Cholesterol
HS - Highly significant
MS - Moderately significant
S - Significant
NS - Not significant 
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